

## MERMAID-1 (AstraZeneca)

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer.

This is the trial summary as assessed on [clinicaltrials.gov](https://clinicaltrials.gov) on 11/02/2021.

Minor changes in the protocol may occur. You can check this on this direct link: <https://clinicaltrials.gov/ct2/show/NCT04385368>

### Trial Design:

Arm	Intervention
Experimental	Durvalumab + SoC chemotherapy – IV
Placebo Comparator	Placebo + SoC chemotherapy - IV

### Inclusion criteria:

1. Capable of giving signed informed consent, which includes a mandatory genetic informed consent and compliance with the requirements and restrictions listed in the informed consent forms (ICFs) and study protocol
2. Age  $\geq 18$  years at the time of screening
3. Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage II-III) disease
4. Complete resection of the primary NSCLC

### Exclusion criteria:

1. Postoperative imaging demonstrating unequivocal evidence of disease recurrence or tissue biopsy-proven disease recurrence
2. EGFR-mutant and/or ALK-translocation
3. Mixed small cell and NSCLC histology
4. Received any prior adjuvant therapy for NSCLC or any prior exposure to durvalumab